Teva has bolstered its respiratory portfolio in the US after launching the first generic version of Viatris’ Perforomist(formoterol fumarate) inhalation solution 20mcg/2ml vial.
The Israeli firm’s launch coincides with the expiry on 22 June of six patents shielding the treatment for chronic obstructive...




